Showing results (901-910 of 996) with videos related to
Sort By:
Pageof 100
NPJ Breast Cancer|June 13, 2023
Racial disparity in tumor microenvironment and distant recurrence in residual breast cancer after neoadjuvant chemotherapyGina Kim, Burcu Karadal-Ferrena, Jiyue Qin, et al.JCO Global Oncology|July 23, 2020
Clinical Trials for Treatment and Prevention of HIV-Associated Malignancies in Sub-Saharan Africa: Building Capacity and Overcoming BarriersLilie L Lin, David S Lakomy, Elizabeth Y Chiao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2018
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102Noah Kornblum, Fengmin Zhao, Judith Manola, et al.JAMA Network Open|July 3, 2025
Quality of Life Among Patients With Ductal Carcinoma In SituVictoria J Dunsmore, Bradley S Snyder, Ilana F Gareen, et al.Nature Ecology & Evolution|July 25, 2018
A decision tree for assessing the risks and benefits of publishing biodiversity dataAyesha I T Tulloch, Nancy Auerbach, Stephanie Avery-Gomm, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2016
Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast CancerHetal Patel, Rezvan Abduljabbar, Chun-Fui Lai, et al.Blood|December 22, 2009
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphomaJoseph A Sparano, Jeannette Y Lee, Lawrence D Kaplan, et al.The Lancet. Oncology|November 28, 2017
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trialSara A Hurvitz, Miguel Martin, W Fraser Symmans, et al.The Breast Journal|July 5, 2012
Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotypingGordon F Schwartz, Harry Bartelink, Harold J Burstein, et al.Journal of the National Cancer Institute|September 22, 2018
Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast CancerJinani Jayasekera, Clyde B Schechter, Joseph A Sparano, et al.Pageof 100